Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Relief Therapeutics Holding SA RLFTF

Relief Therapeutics Holding SA is a based drug development company focusing on clinical stage projects, primarily developing drugs of natural human origin. It is engaged in its operations for diabetic complications and respiratory diseases. The company is focused on developing drug candidates namely, Aviptadil and Atexakin alfa. Aviptadil is a biologically active endogenous human peptide that possesses anti-proliferative, anti-inflammatory, and immune regulatory activities. Atexakin alfa is a low dosage formulation of interleukin-6 that exhibits functions in diverse tissues and organs. The group operates its functions in Switzerland.


Recent & Breaking News (OTCQB:RLFTF)

APR Applied Pharma Research (a Subsidiary of Relief Therapeutics) is a Finalist in the 2022 Rare Disease International Film Festival

Accesswire 8 days ago

Relief Therapeutics Files Amendment No. 1 to its Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission

Accesswire 13 days ago

Relief Therapeutics Holding SA and NRx Pharmaceuticals, inc. Further Extend their Stay of Pending Litigation to Provide Additional Time for the Parties to Finalize their Litigation Settlement

Accesswire November 8, 2022

Relief Therapeutics Announces Six-Month Stability Data on a New Formulation of RLF-100 (Aviptadil)

Accesswire November 7, 2022

RELIEF THERAPEUTICS Holding SA and NRx Pharmaceuticals, Inc. Extend Their Stay of Pending Litigation to Provide Additional Time for The Parties to Finalize Their Settlement

Accesswire October 26, 2022

Relief Therapeutics Files Amendment No. 2 to its Form F-6 Registration Statement with the U.S. Securities and Exchange Commission

Accesswire October 25, 2022

Relief Therapeutics Announces Promotion of Paolo Galfetti to Chief Operating Officer

Accesswire October 14, 2022

Relief Announces U.S. Launch of PKU GOLIKE

Accesswire October 10, 2022

Relief Announces Exclusive Distributor for PKU GOLIKE in the U.S.

Accesswire October 6, 2022

Acer Therapeutics and Relief Therapeutics Announce Receipt of Notice of Allowance of US Patent Application Covering a Kit Comprising Phenylbutyrate and Sodium Benzoate

GlobeNewswire October 3, 2022

Relief Reports Half-Year 2022 Results and Provides Corporate Update

Accesswire September 15, 2022

Relief Therapeutics to Participate in the 22nd Annual Biotech in Europe Forum

Accesswire September 12, 2022

Relief Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

Accesswire September 7, 2022

Relief Therapeutics Files Registration Statement on form F-1 with the U.S. Securities and Exchange Commission

Accesswire August 24, 2022

Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Tentative Settlement of Pending Litigation

Accesswire August 22, 2022

Relief Therapeutics Appoints David McCullough as Head of U.S. Market Access

Accesswire August 17, 2022

Relief Therapeutics and Acer Therapeutics Announce that the European Commission Has Granted Orphan Drug Designation for ACER-001 in Maple Syrup Urine Disease

GlobeNewswire August 12, 2022

Relief Therapeutics Announces Promising Initial Stability Data on a New Formulation of RLF-100(R) (Aviptadil)

Accesswire August 3, 2022

Acer Therapeutics and Relief Therapeutics Announce ACER-001 IND Submission for the Treatment of Maple Syrup Urine Disease

GlobeNewswire July 28, 2022

Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDs

GlobeNewswire July 28, 2022